In addition, in vivo studies demonstrated that Apt–HA–CS–CRISPR/Cas9 exhibited a significant tumor‐suppressive effect and effectively delivered CRISPR/Cas9 to the tumor site, showing no noticeable distribution in other organs in contrast to the unmodified plasmid. This evidence concerns the gene LYPLA2P1 and neoplasm.